pSivida Corp. PSDV, a leader in developing sustained release,
drug delivery products for treatment of back-of-the-eye diseases, announced
today that the Spanish Agency of Drugs and Medical Devices (Agencia Espanola
de Medicamentos y Productos Sanitarios) granted marketing authorization to
ILUVIEN^® for the treatment of vision impairment associated with chronic
diabetic macular edema (DME) considered insufficiently responsive to available
therapies.
The Spanish authorization is the sixth national approval for ILUVIEN in the
EU, preceded by Austria, the United Kingdom, Portugal, France and Germany.
pSivida's licensee Alimera Sciences, Inc. reported that it continues to work
closely with the Italian regulatory authorities to secure marketing
authorization in Italy. These marketing authorizations follow the completion
of the Decentralized Regulatory Procedure (DCP) in the European Union (EU), in
which the Medicines and Healthcare products Regulatory Agency (MHRA) in the
United Kingdom, serving as the Reference Member State (RMS), delivered a
positive outcome for ILUVIEN along with six Concerned Member States (CMS).
Dr. Paul Ashton, President and CEO, said, “We are pleased that ILUVIEN has now
been granted marketing authorizations in six of the seven EU countries in
which approval has been sought and look forward to its commercial launch in
the EU.”
Alimera reported that it continues to expect the initial commercial launch of
ILUVIEN in Germany during the first quarter of 2013 with its European
management team now on board.
The International Diabetes Federation estimates that more than three million
people are currently living with diabetes in Spain, approximately 160,000 of
whom Alimera estimates suffer from vision loss associated with DME.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in